Literature DB >> 20733551

Biomarkers: hypertension following anti-angiogenesis therapy.

Brian I Rini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20733551

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  5 in total

Review 1.  Future directions in renal cell carcinoma: 2011 and beyond.

Authors:  Daniel C Cho; Michael B Atkins
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

2.  Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Authors:  A B Suttle; H A Ball; M Molimard; T E Hutson; C Carpenter; D Rajagopalan; Y Lin; S Swann; R Amado; L Pandite
Journal:  Br J Cancer       Date:  2014-10-28       Impact factor: 7.640

Review 3.  Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.

Authors:  Renate Pichler; Isabel Heidegger
Journal:  Memo       Date:  2017-08-11

4.  Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.

Authors:  Alison C Johnson; Margarida Matias; Helen Boyle; Bernard Escudier; Alicia Molinier; Brigitte Laguerre; Carole Helissey; Pierre-Emmanuel Brachet; Audrey Emmanuelle Dugué; Loic Mourey; Elodie Coquan; Florence Joly
Journal:  BMC Cancer       Date:  2017-05-22       Impact factor: 4.430

5.  Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Authors:  Seon Ha Baek; Hyunsuk Kim; Jeonghwan Lee; Dong Ki Kim; Kook-Hwan Oh; Yon Su Kim; Jin Suk Han; Tae Min Kim; Se-Hoon Lee; Kwon-Wook Joo
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.